
-
Pfizer NYSE:PFE Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Location: 66 Hudson Boulevard East, New York, NY, 10001-2192, United States | Website: https://www.pfizer.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
178.7B
Cash
17.32B
Avg Qtr Burn
N/A
Short % of Float
1.89%
Insider Ownership
0.06%
Institutional Own.
67.57%
Qtr Updated
03/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TALA + enzalutamide Details Cancer, Prostate cancer, Castration-resistant prostate cancer | Approved Update | |
LITFULO™ (Ritlecitinib) Details Alopecia areata | Approved Update | |
Zavzpret (Zavegepant) Details Migraines | Approved Update | |
PADCEV® Details Urothelial carcinoma | Approved Quarterly sales | |
Approved Quarterly sales | ||
Oxbryta (Voxelotor) Details SCD (Sickle Cell Disease) | Approved Quarterly sales | |
HYMPAVZI™ (Marstacimab) Details Hemophilia | Approved Quarterly sales | |
ABRYSVO Details Respiratory syncytial virus, Respiratory virus | Approved Quarterly sales | |
BEQVEZ™ (fidanacogene elaparvovec-dzkt) Details Hemophilia, Hemophilia B | Approved Quarterly sales | |
LORBRENA® Details Cancer, Lung cancer, Non-small cell lung carcinoma | Approved Quarterly sales | |
PREVNAR 20 (20-valent pneumococcal conjugate vaccine) (20vPnC) Details Invasive pneumococcal disease | Approved Quarterly sales | |
ELREXFIO (elranatamab) Details Cancer, Multiple myeloma | Approved Quarterly sales | |
VELSIPITY Details Ulcerative colitis | Approved Quarterly sales | |
Paxlovid Details COVID-19 | Approved Quarterly sales | |
BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Details Cancer, Non-small cell lung carcinoma | Approved Quarterly sales | |
Bivalent Respiratory Syncytial Virus (RSV) Vaccine /RSVpreF (Older adults) Details Respiratory syncytial virus, Respiratory virus | Approved Quarterly sales | |
TIVDAK (tisotumab vedotin-tftv) Details Cervical cancer | Approved Quarterly sales | |
ABRYSVO Details Respiratory syncytial virus, Respiratory virus | Approved Quarterly sales | |
ADCETRIS® (Brentuximab Vedotin) Details Hodgkin Lymphoma | Approved Quarterly sales | |
TUKYSA (Tucatinib) Details Solid tumor/s, Cancer, Metastatic colorectal cancer, Colorectal cancer | Approved Quarterly sales | |
BRAFTOVI® + cetuximab & mFOLFOX6 Details Metastatic colorectal cancer | Approved Quarterly sales | |
PADCEV® + KEYTRUDA® (pembrolizumab) Details Bladder cancer | Approved Quarterly sales | |
TIVDAK (tisotumab vedotin-tftv) Details Cervical cancer | Approved Quarterly sales | |
PENBRAYA Details Meningitis | Approved Quarterly sales | |
Aztreonam-Avibactam (ATM-AVI) Details Pneumonia, Bacterial infection, Intra-abdominal infections | NDA Submission | |
modFlu mRNA Vaccine /PF-07252220 Details Influenza | Phase 3 Data readout | |
Inclacumab (P-selectin inhibitor) Details Sickle cell disease | Phase 3 Data readout | |
IBRANCE (palbociclib) Details Cancer, Breast cancer | Phase 3 Data readout | |
Sasanlimab + BCG Details Non-muscle invasive bladder cancer | Phase 3 Update | |
Phase 3 Update | ||
TUKYSA (Tucatinib) combo Kadcyla Details Cancer, Solid tumor/s, Breast cancer | Phase 3 Update | |
Ponsegromab Details Cancer, Cancer cachexia | Phase 3 Initiation | |
Troriluzole Details Obsessive compulsive disorder | Phase 2/3 Data readout | |
PF-07940367 (GBT021601) Details Sickle cell disease | Phase 2 Data readout | |
ADCETRIS® + pembrolizumab Details Solid tumor/s, Melanoma, Non-small cell lung carcinoma | Phase 2 Data readout | |
Verdiperstat Details Multiple System Atrophy | Failed Discontinued | |
Troriluzole Details Spinocerebellar Ataxia | Failed Discontinued | |
Troriluzole Details Alzheimer's disease | Failed Discontinued | |
Failed Discontinued | ||
Verdiperstat Details Amyotrophic lateral sclerosis | Failed Discontinued | |
Danuglipron Details Obesity, Type 2 diabetes | Failed Discontinued |